A
Annemieke Cats
Researcher at Netherlands Cancer Institute
Publications - 221
Citations - 12256
Annemieke Cats is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Cancer & Capecitabine. The author has an hindex of 50, co-authored 209 publications receiving 10094 citations. Previous affiliations of Annemieke Cats include Leiden University Medical Center & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol,Miriam Koopman,Annemieke Cats,C.J. Rodenburg,Geert Jan Creemers,Jolanda G Schrama,Frans L. G. Erdkamp,A. Vos,Cees J van Groeningen,Harm Sinnige,Dirk J. Richel,Emile E. Voest,Jeroen R. Dijkstra,Marianne E. Vink-Börger,Ninja Antonini,Linda Mol,Johan H. J. M. van Krieken,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life.
Journal ArticleDOI
Genome-wide cell-free DNA fragmentation in patients with cancer
Stephen Cristiano,Alessandro Leal,Jillian Phallen,Jacob Fiksel,Vilmos Adleff,Daniel C. Bruhm,Sarah Østrup Jensen,Jamie E. Medina,Carolyn Hruban,James R. White,Doreen N. Palsgrove,Noushin Niknafs,Valsamo Anagnostou,Patrick M. Forde,Jarushka Naidoo,Kristen A. Marrone,Julie R. Brahmer,Brian Woodward,Hatim Husain,Karlijn L. van Rooijen,Mai Britt Worm Ørntoft,Anders Husted Madsen,Cornelis J.H. van de Velde,Marcel Verheij,Annemieke Cats,Cornelis J. A. Punt,Geraldine R. Vink,Nicole C.T. van Grieken,Miriam Koopman,Remond J.A. Fijneman,Julia S. Johansen,Hans Jørgen Nielsen,Gerrit A. Meijer,Claus L. Andersen,Robert B. Scharpf,Victor E. Velculescu +35 more
TL;DR: An approach to evaluate fragmentation patterns of cell-free DNA across the genome was developed, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles.
Journal ArticleDOI
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.
Rachel S. van der Post,Ingrid P. Vogelaar,Fátima Carneiro,Parry Guilford,David G. Huntsman,Nicoline Hoogerbrugge,Carlos Caldas,Karen E Chelcun Schreiber,Richard H. Hardwick,Margreet G. E. M. Ausems,Linda Bardram,Patrick R. Benusiglio,Tanya M. Bisseling,Vanessa Blair,Eveline M. A. Bleiker,Alex Boussioutas,Annemieke Cats,Daniel G. Coit,Lynn DeGregorio,Joana Figueiredo,James M. Ford,Esther Heijkoop,Rosella P.M.G. Hermens,Bostjan Humar,Pardeep Kaurah,G. Keller,Jennifer Lai,Marjolijn J. L. Ligtenberg,Maria O'Donovan,Carla Oliveira,Hugo Pinheiro,Krish Ragunath,Esther Rasenberg,Susan Richardson,Franco Roviello,Hans K. Schackert,Raquel Seruca,Amy E Taylor,Anouk ter Huurne,Marc Tischkowitz,Sheena Tjon A Joe,Benjamin van Dijck,Nicole C.T. van Grieken,Richard van Hillegersberg,Johanna W. van Sandick,Rianne Vehof,J. Han van Krieken,Rebecca C. Fitzgerald +47 more
TL;DR: The updated guidelines include revised CDH1 testing criteria, which could be considered in patients with bilateral or familial LBC before the age of 50, patients with DGC and cleft lip/palate, and those with precursor lesions for signet ring cell carcinoma.
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Annemieke Cats,Edwin P.M. Jansen,Nicole C.T. van Grieken,Karolina Sikorska,Pehr Lind,Marianne Nordsmark,Elma Meershoek-Klein Kranenbarg,Henk Boot,Anouk K. Trip,HA A. Maurits Swellengrebel,Hanneke W. M. van Laarhoven,Hein Putter,Johanna W. van Sandick,Mark I. van Berge Henegouwen,Henk H. Hartgrink,Harm van Tinteren,Cornelis J.H. van de Velde,Marcel Verheij,Frits van Coevorden,Steven Vanhoutvin,Maarten C.C.M. Hulshof,Olaf Jl Loosveld,A (Bert) Jan Ten Tije,Frans L. G. Erdkamp,Fabiënne A. R. M. Warmerdam,Donald L. van der Peet,Henk M.W. Verheul,Djamila Boerma,Maartje Los,Annerie Slot,Danny Houtsma,Johanna E.A. Portielje,Reinoud J. B. Blaisse,Ernst Jan Spillenaar Bilgen,Marco B Polée,Maud M. Geenen,Jeffrey P.B.M. Braak,Karen J. Neelis,Marije Slingerland,Rob L. H. Jansen,Jeroen Buijsen,Aart Beeker,Quirijn A. J. Eijsbouts,Johanna Mgh Van Riel,Tom Rozema,Dick Johan van Spronsen,Jetske M. Meerum Terwogt,Bea C Tanis,Adelheid Me Van der Torren-Conze,Richard Van Hilligersberg,Miriam Koopman,Marien O Den Boer,Geert-Jan Creemers,Maurice J.C. van der Sangen,Marjolein Em Rentinck,H Pieter van den Berg,Ge Jpm Jonkers,Diane Grootenboers,Annelie Je Vulink,Sjoerd Hovenga,Huub van der Mijle,Arnold Baars,A. Haringhuizen,Marije Ie Appels,Ron C Rietbroek,Ellen M Hendriksen,Marie-Cecile Jc Legdeur,Daan Ten Bokkel Huinink,O Aart Van Dobbenburgh,Jitty M Smit,Aart Van Bochove,Gerrit-Jan Veldhuis,Erik W Muller,Johannes J. Bonenkamp,Pètra M Braam,Jaap De Boer,Henk K Van Halteren,Fransje Aa Valster,Alex L. T. Imholz,Marjan A Van Dijk,Ate van der Gaast,J (Hans)-Martin Mb Otten,Heleen M. Ceha,Bengt Glimelius,Cecillia Lagerbäck,Mats Perman,Anders Johnsson,David Borg,Niels H Nielsen,Andrzej Piwowar,Mattias Elmlund,Helene Hörberg,Per Edlund,Bengt Johansson,Petra Flygare,Marie Louise Jespersen +95 more
TL;DR: This investigator-initiated, open-label, randomised phase 3 trial aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma.